Breakthrough in CRISPR-Based Therapy: FDA Accepts Vertex and CRISPR Therapeutics’ Exa-cel Application
The FDA has accepted the application for Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics AG CRSP exa-cel for sickle cell disease and transfusion-dependent beta-thalassemia (TDT). The FDA...